Adragos Pharma is a globally operating Contract Development and Manufacturing Organisation (CDMO) for pharmaceuticals.

Headquartered in Germany, Adragos Pharma operates three production sites in France, Germany, and Japan focused on the production of finished dosage forms (FDF) pharmaceuticals in the small-molecule segment. Its sites cover relevant technologies in sterile and non-sterile liquids and semi-solids, providing end-to-end services for its large base of pharma customers.

 

Investment Thesis

  • The market for CDMOs is growing faster than the overall pharma industry due to the continued outsourcing trends propelling the CDMO industry
  • As part of their outsourcing strategy, large pharma companies are divesting underutilized production sites to optimize their site networks and product portfolios
  • This divestment trend creates a significant runway of add-on opportunities for CDMOs with track-record and capabilities to take over and optimize these sites

Main Transformation Initiatives

  • Expand existing site network via add-on acquisitions in Europe and NA
  • Continue to expand development capabilities
  • Grow and professionalize organization and business processes

Key Facts

Country Germany, France, Japan

Headquarter Munich

Acquired 2021-09

FSN Ownership 77%

Sales 2020 EUR 45m

CEO Dr. Andreas Raabe

Pointperson Nicolai Norrbom

Webpage www.adragos-pharma.com

Norway (Visiting address)
FSN Capital Partners AS
Dronning Mauds Gate 11
0250 Oslo
Norway
+47 24 14 73 00

 

Sweden
FSN Capital Partners AB
Birger Jarlsgatan 15
111 45 Stockholm
Sweden
+46 85 450 39 30

Norway (Post address)
FSN Capital Partners AS
PO. Box 1597
0118 Vika
Norway
 

Germany
FSN Capital Partners GmbH
Brienner Straße 7
80333, München/Munich
Germany
+49 160 3666 627

Denmark
FSN Capital Partners Aps
Kongens Nytorv 26, 2. Sal
1050 Copenhagen
Denmark
+45 33 13 48 00